Q2 Earnings Forecast for Liquidia Issued By Lifesci Capital

Liquidia Co. (NASDAQ:LQDA - Free Report) - Research analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Liquidia in a report issued on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Liquidia's current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia's Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.41) EPS.

Other equities research analysts have also issued research reports about the stock. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research report on Thursday, March 20th. Needham & Company LLC increased their price objective on Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Liquidia has a consensus rating of "Buy" and a consensus price target of $26.63.

Liquidia Stock Up 2.5 %

LQDA stock traded up $0.37 during trading hours on Monday, hitting $15.24. The company's stock had a trading volume of 525,027 shares, compared to its average volume of 930,226. The stock has a 50 day moving average price of $15.01 and a two-hundred day moving average price of $12.34. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.81. The company has a market capitalization of $1.30 billion, a PE ratio of -9.35 and a beta of 0.07.

Remove Ads

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

Insider Activity at Liquidia

In other news, CFO Michael Kaseta sold 23,370 shares of the company's stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $275,298.60. Following the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Rajeev Saggar sold 2,445 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the sale, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock worth $843,326 in the last ninety days. 30.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Liquidia during the 4th quarter worth about $59,000. Summit Investment Advisors Inc. lifted its position in Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after purchasing an additional 1,719 shares during the period. Walleye Trading LLC boosted its stake in shares of Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company's stock valued at $132,000 after purchasing an additional 4,670 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia during the fourth quarter worth approximately $142,000. Finally, EntryPoint Capital LLC acquired a new position in Liquidia in the fourth quarter valued at approximately $154,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).